The absence of Fc-directed CDC/ADCC functions requirement for anti-GD2 mAb anti-tumor efficacy in vivo was also suggested by Mujoo et al. [24] who studied the anti-tumor properties of mouse IgG3 mAb 14.18 and its isotype switch variants. This evidence concerns the gene IGHG3 and neoplasm.